Understanding the lethal variant of prostate cancer: Power of examining extremes

Cancer Discovery

Volumn 1, Issue 6, 2011, Pages 466-468

  Aparicio, Ana ^a   Logothetis, Christopher J ^a   Maity, Sankar N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISERTIB; AURORA A KINASE; BRCA1 PROTEIN; DANUSERTIB; MYC PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

ARTICLE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE REGULATION; EMBRYO DEVELOPMENT; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CARCINOMA; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; HUMANS; MALE; NEUROENDOCRINE TUMORS; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 84866683064     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-11-0259     Document Type: Article

References (10)

1. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized Small cell carcinoma of the prostate. J Clin Oncol 2002;20:3072-80.
2. Clegg N, Ferguson C, True LD, Arnold H, Moorman A, Quinn JE, et al. Molecular characterization of prostatic Small cell neuroendocrine carcinoma. Prostate 2003;55:55-64.
3. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, et al. Neuroendocrine prostate cancer xenografts with large-cell and Small cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 2011;71:846-56.
4. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discovery 1:487-95;2011.
5. Westermark UK, Wilhelm M, Frenzel A, Henriksson MA. The MYCN oncogene and differentiation in neuroblastoma. Semin Cancer Biol 2011 Aug 9. [Epub ahead of print].
6. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010;10:825-41.
7. Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007;6:3158-68.
8. Bleuse JP, Meulenbeld HJ, Vinci EM, Raymond E, Vitali A, Santoro L, et al. Randomized phase II study of danusertib (D) in second-line metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2011;29:suppl, abstr 4628.
9. Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010;55:26-34.
10. Otto T, Horn S, Brockmann M, Eilers U, Schüttrumpf L, Popov N, et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009;15:67-78.